Financial Overview (in millions, except share amounts)

  2008 2009 % Change

1 Adjusted to exclude a patent litigation gain of $42.9 million ($0.11 per share) and income taxes on repatriation of foreign earnings of $67.1 million ($0.17 per share) recorded in 2009, as well as restructuring charges of $48.4 million ($0.12 per share) and $21.7 million ($0.05 per share) recorded in 2009 and 2008, respectively.
Sales $ 6,718.2 $ 6,723.1 0.1
Earnings before income taxes 1,580.2 1,623.9 2.8
Income taxes 432.4 516.5 19.4
Net earnings 1,147.8 1,107.4 (3.5)
Adjusted net earnings1 1,169.5 1,180.0 0.9
Diluted net earnings per share of common stock:      
Reported $ 2.78 $ 2.77 (0.4)
Adjusted1 $ 2.83 $ 2.95 4.2
Dividends paid per share of common stock 0.33 0.50 51.5
Cash and current marketable securities 2,195.6 2,954.8 34.6
Dividens Paid ($ per share)
  2003 2004 2005 2006 2007 2008 2009
Amount paid — 0.07 0.09 0.11 0.22 0.23 0.50
Cash Flow Provided by Operating Activities
  2003 2004 2005 2006 2007 2008 2009
Amount 617 560 833 867 1,028 1,176 1,461
Leveraged Earnings Growth ($ PER SHARE)
  2003 2004 2005 2006 2007 2008 2009
Amount 1.03 1.37 1.66 2.00 2.40 2.83 2.95

Adjusted to exclude certain charges and gains, including patent litigation, restructurings, intangible asset impairment,in-process research and development, income taxes on repatriation of foreign earnings, acquisition-related items and discontinued operations.

Worldwide Sales Growth: 2.4 Billion, International, 4.3 Billion, U.S., totaling 6.7 billion worldwide.

Chart showing revenue growth between 1979, $0, to 2009, $6.7 Billion

Diversified Sales Base

  • Reconstructive Implants: 38%
    • Hips: 16%
    • Knees: 19%
    • Extremity/Other: 3%
  • Spine, Trauma & CMF Implants: 23%
    • Trauma: 11%
    • Spine: 9%
    • CMF/Other: 3%
  • Medical/Surgical: 39%
    • Instruments: 18%
    • Endoscopy: 14%
    • Medical: 7%

© Stryker 2010